H.C. Wainwright cuts Purple Biotech stock price target on preclinical progress

Investing.com•Mon, Aug 10, 2026, 11:41 AM•2 min read

Developing story — details emerging. Check the source link for the latest updates.

Source: [Investing.com](https://www.investing.com/news/analyst-ratings/hc-wainwright-cuts-purple-biotech-stock-price-target-on-preclinical-progress-93CH-4848848)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at Investing.com ↗

#finance #wainwright #cuts #purple #biotech #stock #price #target #preclinical

More Headlines

AI & MLOpenAI Blog• 5m ago

What building an AI-native finance function taught me

OpenAI CFO Sarah Friar shares five lessons for building an AI-native finance function, from automated forecasting to stronger controls and AI ROI.

FinanceCNBC• 5m ago

Oil in U.S. Strategic Petroleum Reserve falls below 300 million barrels, lowest since 1983

U. S. presidents have ordered massive releases from the SPR with growing frequence in recent years.

FinanceSeeking Alpha• 9m ago

My Income Portfolio: The Music Of Dividends

Developing story — details emerging. Check the source link for the latest updates.

FinanceMarketWatch• 17m ago

Protect College Sports Act to be voted on next month: What it means for transfers and team spending

Here’s how the Protect College Sports Act could impact the economics of college sports.

FinanceSeeking Alpha• 18m ago

Criteo: No Light At The End Of The Tunnel As Top Line Deteriorates (Rating Downgrade)

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 22m ago

3D Systems: Recovery Is Gaining Momentum, But Valuation Leaves Little Room For Error

Developing story — details emerging. Check the source link for the latest updates.